NxStage Medical Company Profile (NASDAQ:NXTM)

About NxStage Medical (NASDAQ:NXTM)

NxStage Medical logoNxStage Medical, Inc. is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets. The In-Center segment includes revenues from the sale of blood tubing sets and needles for hemodialysis, primarily for the treatment of end-stage renal disease patients at dialysis clinics, and needles for apheresis. It markets extracorporeal disposable products under the Medisystems brand. The Services segment includes revenues from dialysis services provided to patients at its NxStage Kidney Care dialysis centers. Its product offerings include Home Dialysis, Next-Generation Hemodialysis System, Critical Care, Next-Generation Critical Care System and In-Center.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Imaging Systems
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:NXTM
  • CUSIP: 67072V10
  • Web: www.nxstage.com
  • Market Cap: $1.83114 billion
  • Outstanding Shares: 66,130,000
Average Prices:
  • 50 Day Moving Avg: $27.80
  • 200 Day Moving Avg: $25.85
  • 52 Week Range: $20.45 - $30.80
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 307.67
  • P/E Growth: -27.47
Sales & Book Value:
  • Annual Revenue: $378.01 million
  • Price / Sales: 4.84
  • Book Value: $3.28 per share
  • Price / Book: 8.44
  • EBIDTA: $14.26 million
  • Net Margins: -1.33%
  • Return on Equity: -2.43%
  • Return on Assets: -1.56%
  • Current Ratio: 3.34%
  • Quick Ratio: 2.24%
  • Average Volume: 1.51 million shs.
  • Beta: 0.08
  • Short Ratio: 10.23

Frequently Asked Questions for NxStage Medical (NASDAQ:NXTM)

What is NxStage Medical's stock symbol?

NxStage Medical trades on the NASDAQ under the ticker symbol "NXTM."

How were NxStage Medical's earnings last quarter?

NxStage Medical, Inc. (NASDAQ:NXTM) posted its earnings results on Monday, August, 7th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.00. The firm had revenue of $92.20 million for the quarter, compared to analysts' expectations of $96.47 million. NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. NxStage Medical's revenue for the quarter was up .0% compared to the same quarter last year. During the same period last year, the firm earned ($0.03) earnings per share. View NxStage Medical's Earnings History.

When will NxStage Medical make its next earnings announcement?

NxStage Medical is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for NxStage Medical.

Where is NxStage Medical's stock going? Where will NxStage Medical's stock price be in 2017?

8 equities research analysts have issued 1-year price targets for NxStage Medical's shares. Their predictions range from $27.00 to $32.00. On average, they anticipate NxStage Medical's stock price to reach $29.86 in the next year. View Analyst Ratings for NxStage Medical.

What are analysts saying about NxStage Medical stock?

Here are some recent quotes from research analysts about NxStage Medical stock:

  • 1. According to Zacks Investment Research, "NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. " (8/11/2017)
  • 2. Northland Securities analysts commented, "We continue to move our PD program forward at an impressive pace…We continue to firmly believe that by keeping our regulatory timelines and pathway confidential, we’re protecting a significant value opportunity. Let me be clear, we both have the opportunity to do great things for patients, bringing new technology to the market that makes PD easier and better." (8/7/2017)
  • 3. Jefferies Group LLC analysts commented, "Home hemodialysis (HHD) in skilled nursing facilities (SNF) is a significant opportunity for NXTM. HHD penetration is already approaching 6% in the most developed states v. less than 2% for the market as a whole; a disparity explained to a large degree by SNF adoption. The regulatory underpinnings can be debated, but even modest assumptions for continued adoption in SNFs supports 20%+ revenue growth at NXTM. We raise our PT to $38, 5x 2018 sales." (2/6/2017)

Are investors shorting NxStage Medical?

NxStage Medical saw a decline in short interest in August. As of August 15th, there was short interest totalling 2,234,165 shares, a decline of 26.3% from the July 31st total of 3,031,024 shares. Based on an average daily volume of 4,648,616 shares, the days-to-cover ratio is currently 0.5 days. Approximately 3.5% of the shares of the company are sold short.

Who are some of NxStage Medical's key competitors?

Who are NxStage Medical's key executives?

NxStage Medical's management team includes the folowing people:

  • Robert G. Funari, Independent Chairman of the Board
  • Joseph E. Turk Jr., President
  • Jeffrey H. Burbank, Chief Executive Officer, Director
  • Matthew W. Towse CPA, Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
  • Robert S. Brown, President of NxStage Kidney Care
  • Winifred L. Swan J.D., Senior Vice President, General Counsel
  • Heyward R. Donigan, Independent Director
  • Daniel A. Giannini CPA,, Independent Director
  • Earl R. Lewis, Independent Director
  • Jean K. Mixer, Independent Director

Who owns NxStage Medical stock?

NxStage Medical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (7.95%), BlackRock Inc. (6.34%), Eagle Asset Management Inc. (3.92%), Gilder Gagnon Howe & Co. LLC (3.35%) and William Blair Investment Management LLC (2.98%). Company insiders that own NxStage Medical stock include Barry M Straube, Craig W Moore, Daniel A Giannini, Earl R Lewis, Jeffrey H Burbank, Joseph E Turk Jr, Joseph E Turk, Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Institutional Ownership Trends for NxStage Medical.

Who sold NxStage Medical stock? Who is selling NxStage Medical stock?

NxStage Medical's stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Jennison Associates LLC, Wells Fargo & Company MN, Victory Capital Management Inc., BlackRock Inc., Blair William & Co. IL, Sectoral Asset Management Inc and Broadview Advisors LLC. Company insiders that have sold NxStage Medical stock in the last year include Craig W Moore, Daniel A Giannini, Jeffrey H Burbank, Joseph E Turk Jr, Matthew W Towse, Robert S Brown and Winifred L Swan. View Insider Buying and Selling for NxStage Medical.

Who bought NxStage Medical stock? Who is buying NxStage Medical stock?

NxStage Medical's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, William Blair Investment Management LLC, Redmile Group LLC, Eagle Asset Management Inc., Marshall Wace North America L.P., Bank of Montreal Can, Koch Industries Inc. and Delta Lloyd Asset Management N.V.. Company insiders that have bought NxStage Medical stock in the last two years include Barry M Straube and Earl R Lewis. View Insider Buying and Selling for NxStage Medical.

How do I buy NxStage Medical stock?

Shares of NxStage Medical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NxStage Medical's stock price today?

One share of NxStage Medical stock can currently be purchased for approximately $27.69.

MarketBeat Community Rating for NxStage Medical (NASDAQ NXTM)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  148 (Vote Underperform)
Total Votes:  366
MarketBeat's community ratings are surveys of what our community members think about NxStage Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NxStage Medical (NASDAQ:NXTM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 8 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $29.86 (7.83% upside)

Analysts' Ratings History for NxStage Medical (NASDAQ:NXTM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/22/2017Leerink SwannDowngradeOutperform -> Market Perform$28.00 -> $30.00HighView Rating Details
8/11/2017BTIG ResearchDowngradeBuy -> NeutralLowView Rating Details
8/9/2017StephensDowngradeOverweight -> Equal Weight$33.00 -> $30.00LowView Rating Details
8/8/2017Jefferies Group LLCDowngradeBuy -> Hold$33.00 -> $30.00MediumView Rating Details
8/7/2017William BlairDowngradeOutperform -> Market PerformMediumView Rating Details
8/7/2017Canaccord GenuityDowngradeBuy -> Hold$30.00MediumView Rating Details
8/7/2017Northland SecuritiesReiterated RatingHold$30.00LowView Rating Details
8/7/2017Craig HallumDowngradeBuy -> HoldHighView Rating Details
6/3/2016Piper Jaffray CompaniesReiterated RatingBuy$21.00N/AView Rating Details
5/5/2016Wells Fargo & CompanyReiterated RatingSellN/AView Rating Details
12/11/2015Sterne Agee CRTInitiated CoverageBuyN/AView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for NxStage Medical (NASDAQ:NXTM)
Earnings by Quarter for NxStage Medical (NASDAQ:NXTM)
Earnings History by Quarter for NxStage Medical (NASDAQ NXTM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017N/AView Earnings Details
8/7/2017Q2 2017($0.03)($0.03)$96.47 million$92.20 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.03)($0.02)$95.31 million$96.83 millionViewListenView Earnings Details
2/28/2017Q416($0.02)($0.02)$91.82 million$93.01 millionViewListenView Earnings Details
8/4/2016Q216($0.04)($0.03)$89.44 million$92.20 millionViewN/AView Earnings Details
5/4/2016Q116($0.05)($0.02)$88.40 million$89.20 millionViewListenView Earnings Details
2/10/2016Q415($0.04)($0.04)$86.83 million$89.80 millionViewListenView Earnings Details
11/3/2015Q315($0.08)($0.03)$82.06 million$86.50 millionViewN/AView Earnings Details
8/6/2015Q215($0.10)($0.08)$79.89 million$80.30 millionViewListenView Earnings Details
5/6/2015Q115($0.11)($0.09)$77.92 million$79.50 millionViewListenView Earnings Details
2/26/2015Q414($0.10)($0.08)$75.75 million$79.90 millionViewListenView Earnings Details
11/6/2014Q3($0.13)($0.07)$71.83 million$75.30 millionViewN/AView Earnings Details
8/7/2014Q214($0.11)($0.12)$70.52 million$74.10 millionViewN/AView Earnings Details
5/8/2014Q114($0.11)($0.09)$69.44 million$72.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.08)$67.66 million$69.40 millionViewN/AView Earnings Details
11/7/2013Q313$0.22($0.08)$124.03 million$66.90 millionViewListenView Earnings Details
7/25/2013Q2 2013($0.07)($0.06)$64.66 million$65.50 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.08)($0.08)$61.14 million$61.60 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.05)($0.04)$63.54 million$65.00 millionViewN/AView Earnings Details
11/8/2012Q312($0.06)($0.04)$60.90 million$61.00 millionViewN/AView Earnings Details
8/8/2012($0.09)($0.09)ViewN/AView Earnings Details
5/8/2012($0.09)($0.09)ViewN/AView Earnings Details
2/29/2012($0.09)($0.08)ViewN/AView Earnings Details
11/3/2011($0.10)($0.10)ViewN/AView Earnings Details
8/3/2011($0.10)($0.10)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NxStage Medical (NASDAQ:NXTM)
2017 EPS Consensus Estimate: ($0.03)
2018 EPS Consensus Estimate: $0.11
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.03)($0.02)($0.02)
Q2 20173($0.03)$0.00($0.02)
Q3 20173($0.01)$0.01$0.00
Q4 20173$0.00$0.02$0.01
Q1 20182$0.01$0.02$0.02
Q2 20182$0.01$0.01$0.01
Q3 20182$0.02$0.05$0.04
Q4 20182$0.04$0.05$0.05
(Data provided by Zacks Investment Research)


Dividend History for NxStage Medical (NASDAQ:NXTM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NxStage Medical (NASDAQ:NXTM)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 92.75%
Insider Trades by Quarter for NxStage Medical (NASDAQ:NXTM)
Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)
Insider Trades by Quarter for NxStage Medical (NASDAQ:NXTM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2017Matthew W TowseSVPSell4,300$27.27$117,261.00View SEC Filing  
9/5/2017Joseph E Turk JrPresidentSell1,000$27.95$27,950.00View SEC Filing  
8/21/2017Matthew W TowseSVPSell4,300$29.22$125,646.00View SEC Filing  
8/15/2017Winifred L SwanSVPSell3,500$29.21$102,235.00View SEC Filing  
8/10/2017Joseph E Turk JrPresidentSell1,000$29.26$29,260.00View SEC Filing  
8/7/2017Joseph E Turk JrPresidentSell24,000$29.64$711,360.00View SEC Filing  
8/3/2017Joseph E Turk JrPresidentSell7,000$22.98$160,860.00View SEC Filing  
7/20/2017Matthew W TowseSVPSell4,300$24.16$103,888.00View SEC Filing  
7/5/2017Joseph E Turk JrPresidentSell1,000$25.19$25,190.00View SEC Filing  
6/20/2017Matthew W TowseSVPSell4,300$23.29$100,147.00View SEC Filing  
6/15/2017Winifred L SwanSVPSell3,500$23.14$80,990.00View SEC Filing  
6/14/2017Joseph E Turk JrPresidentSell1,000$23.74$23,740.00View SEC Filing  
5/22/2017Matthew W TowseSVPSell4,300$21.36$91,848.00View SEC Filing  
5/15/2017Winifred L SwanSVPSell3,500$21.94$76,790.00View SEC Filing  
5/10/2017Joseph E Turk JrPresidentSell250$23.59$5,897.50View SEC Filing  
5/3/2017Joseph E Turk JrPresidentSell1,000$29.95$29,950.00View SEC Filing  
4/20/2017Jeffrey H BurbankCEOSell3,000$27.28$81,840.00View SEC Filing  
4/20/2017Matthew W TowseSVPSell4,300$27.28$117,304.00View SEC Filing  
4/19/2017Jeffrey H BurbankCEOSell3,000$26.65$79,950.00View SEC Filing  
4/13/2017Joseph E Turk JrPresidentSell1,000$26.10$26,100.00View SEC Filing  
4/3/2017Robert S BrownInsiderSell14,397$26.60$382,960.20View SEC Filing  
3/22/2017Jeffrey H BurbankCEOSell3,000$27.42$82,260.00View SEC Filing  
3/21/2017Jeffrey H BurbankCEOSell3,000$27.72$83,160.00View SEC Filing  
3/20/2017Winifred L SwanSVPSell15,723$27.66$434,898.18View SEC Filing  
3/16/2017Craig W MooreDirectorSell1,000$27.93$27,930.00View SEC Filing  
3/8/2017Joseph E Turk JrPresidentSell1,000$27.53$27,530.00View SEC Filing  
3/7/2017Robert S BrownInsiderSell20,000$27.75$555,000.00View SEC Filing  
3/6/2017Robert S BrownInsiderSell6,390$28.01$178,983.90View SEC Filing  
2/23/2017Jeffrey H BurbankCEOSell7,500$28.97$217,275.00View SEC Filing  
2/22/2017Jeffrey H BurbankCEOSell7,500$29.01$217,575.00View SEC Filing  
2/17/2017Joseph E Turk JrPresidentSell6,000$29.66$177,960.00View SEC Filing  
2/15/2017Winifred L SwanSVPSell16,049$28.01$449,532.49View SEC Filing  
2/14/2017Robert S BrownInsiderSell2,448$28.28$69,229.44View SEC Filing  
2/10/2017Joseph E Turk JrPresidentSell3,500$28.36$99,260.00View SEC Filing  
2/8/2017Robert S BrownInsiderSell3,054$27.61$84,320.94View SEC Filing  
2/7/2017Robert S BrownInsiderSell3,117$27.54$85,842.18View SEC Filing  
2/6/2017Robert S BrownInsiderSell16,283$26.87$437,524.21View SEC Filing  
2/2/2017Joseph E Turk JrPresidentSell15,669$26.19$410,371.11View SEC Filing  
2/2/2017Robert S BrownInsiderSell37,347$26.68$996,417.96View SEC Filing  
1/26/2017Robert S BrownInsiderSell42,000$26.05$1,094,100.00View SEC Filing  
1/23/2017Robert S BrownInsiderSell21,615$26.20$566,313.00View SEC Filing  
1/20/2017Matthew W TowseSVPSell4,300$26.19$112,617.00View SEC Filing  
1/18/2017Jeffrey H BurbankCEOSell7,500$27.63$207,225.00View SEC Filing  
1/18/2017Robert S BrownInsiderSell8,183$27.58$225,687.14View SEC Filing  
1/17/2017Jeffrey H BurbankCEOSell7,500$27.52$206,400.00View SEC Filing  
1/17/2017Robert S BrownInsiderSell10,805$27.72$299,514.60View SEC Filing  
1/13/2017Joseph E Turk JrPresidentSell7,500$28.00$210,000.00View SEC Filing  
1/11/2017Joseph E Turk JrPresidentSell1,000$27.77$27,770.00View SEC Filing  
12/20/2016Matthew W TowseSVPSell4,300$25.55$109,865.00View SEC Filing  
12/15/2016Winifred L SwanSVPSell3,500$25.91$90,685.00View SEC Filing  
12/14/2016Jeffrey H BurbankCEOSell7,500$25.68$192,600.00View SEC Filing  
12/13/2016Jeffrey H BurbankCEOSell7,500$25.42$190,650.00View SEC Filing  
12/13/2016Joseph E Turk JrPresidentSell1,000$25.42$25,420.00View SEC Filing  
11/28/2016Joseph E Turk JrPresidentSell12,169$26.01$316,515.69View SEC Filing  
11/23/2016Jeffrey H BurbankCEOSell7,500$24.01$180,075.00View SEC Filing  
11/22/2016Jeffrey H BurbankCEOSell7,500$25.51$191,325.00View SEC Filing  
11/22/2016Winifred L SwanSVPSell3,000$25.51$76,530.00View SEC Filing  
11/21/2016Daniel A GianniniDirectorSell6,449$25.96$167,416.04View SEC Filing  
11/21/2016Matthew W TowseSVPSell4,300$26.23$112,789.00View SEC Filing  
11/17/2016Joseph E Turk JrPresidentSell1,000$25.97$25,970.00View SEC Filing  
11/16/2016Joseph E Turk JrPresidentSell22,500$26.26$590,850.00View SEC Filing  
9/14/2016Craig W MooreDirectorSell3,000$23.31$69,930.00View SEC Filing  
5/12/2016Joseph E Turk JrPresidentSell1,500$17.89$26,835.00View SEC Filing  
5/10/2016Joseph E Turk JrPresidentSell1,057$18.00$19,026.00View SEC Filing  
4/21/2016Joseph E Turk JrPresidentSell2,000$15.73$31,460.00View SEC Filing  
4/14/2016Winifred L SwanSVPSell6,260$16.40$102,664.00View SEC Filing  
4/5/2016Joseph E Turk JrPresidentSell2,500$15.05$37,625.00View SEC Filing  
3/22/2016Joseph E Turk JrPresidentSell2,000$14.34$28,680.00View SEC Filing  
3/14/2016Winifred L SwanSVPSell620$15.69$9,727.80View SEC Filing  
3/10/2016Joseph E Turk JrPresidentSell2,500$15.58$38,950.00View SEC Filing  
2/24/2016Barry M StraubeDirectorBuy1,500$14.20$21,300.00View SEC Filing  
2/24/2016Joseph E Turk JrPresidentSell2,992$14.12$42,247.04View SEC Filing  
2/16/2016Winifred L. SwanSVPSell2,500$14.07$35,175.00View SEC Filing  
2/12/2016Earl R. LewisDirectorBuy21,000$14.63$307,230.00View SEC Filing  
2/10/2016Joseph E. Turk, Jr.PresidentSell991$16.25$16,103.75View SEC Filing  
2/9/2016Joseph E. Turk, Jr.PresidentSell2,500$16.88$42,200.00View SEC Filing  
2/4/2016Joseph E. Turk, Jr.PresidentSell991$19.60$19,423.60View SEC Filing  
1/20/2016Joseph E Turk JrPresidentSell2,000$18.75$37,500.00View SEC Filing  
1/14/2016Winifred L. SwanSVPSell620$19.04$11,804.80View SEC Filing  
1/11/2016Matthew W. TowseSVPSell3,472$20.40$70,828.80View SEC Filing  
1/8/2016Joseph E. Turk, Jr.PresidentSell1,500$21.03$31,545.00View SEC Filing  
1/7/2016Joseph E. Turk, Jr.PresidentSell3,713$20.78$77,156.14View SEC Filing  
12/22/2015Joseph E. Turk, Jr.PresidentSell5,000$20.92$104,600.00View SEC Filing  
12/16/2015Joseph E. Turk, Jr.PresidentSell800$19.99$15,992.00View SEC Filing  
12/15/2015Matthew W. TowseSVPSell2,863$19.51$55,857.13View SEC Filing  
12/14/2015Winifred L. SwanSVPSell2,500$18.90$47,250.00View SEC Filing  
12/10/2015Jeffrey H. BurbankCEOSell9,274$18.94$175,649.56View SEC Filing  
12/8/2015Joseph E. Turk, Jr.PresidentSell2,913$19.38$56,453.94View SEC Filing  
11/20/2015Craig W MooreDirectorSell1,000$20.00$20,000.00View SEC Filing  
11/19/2015Joseph E Turk JrPresidentSell2,000$19.65$39,300.00View SEC Filing  
11/18/2015Craig W MooreDirectorSell4,000$19.60$78,400.00View SEC Filing  
11/16/2015Winifred L. SwanSVPSell2,500$19.65$49,125.00View SEC Filing  
11/12/2015Joseph E. Turk, Jr.PresidentSell4,055$20.44$82,884.20View SEC Filing  
11/10/2015Jeffrey H. BurbankCEOSell10,000$20.75$207,500.00View SEC Filing  
11/10/2015Joseph E. Turk, Jr.PresidentSell7,500$21.03$157,725.00View SEC Filing  
11/10/2015Matthew W. TowseSVPSell2,863$20.32$58,176.16View SEC Filing  
11/9/2015Daniel A GianniniDirectorSell6,593$20.30$133,837.90View SEC Filing  
11/9/2015Jeffrey H. BurbankCEOSell10,000$20.32$203,200.00View SEC Filing  
11/4/2015Joseph E. Turk, Jr.PresidentSell4,826$19.62$94,686.12View SEC Filing  
11/4/2015Matthew W. TowseSVPSell8,591$19.50$167,524.50View SEC Filing  
11/3/2015Robert S. BrowninsiderSell44,400$19.00$843,600.00View SEC Filing  
10/20/2015Joseph E. Turk, Jr.PresidentSell2,000$15.80$31,600.00View SEC Filing  
10/16/2015Jeffrey H. BurbankCEOSell10,000$15.59$155,900.00View SEC Filing  
10/15/2015Jeffrey H. BurbankCEOSell10,000$14.98$149,800.00View SEC Filing  
10/14/2015Winifred L. SwanSVPSell2,500$15.46$38,650.00View SEC Filing  
10/8/2015Joseph E. Turk, Jr.PresidentSell2,839$15.42$43,777.38View SEC Filing  
9/24/2015Joseph E Turk JrPresidentSell2,000$17.26$34,520.00View SEC Filing  
9/17/2015Jeffrey H. BurbankCEOSell10,000$16.18$161,800.00View SEC Filing  
9/16/2015Jeffrey H. BurbankCEOSell10,000$15.99$159,900.00View SEC Filing  
9/15/2015Craig W MooreDirectorSell1,000$16.00$16,000.00View SEC Filing  
9/14/2015Winifred L. SwanSVPSell2,500$16.01$40,025.00View SEC Filing  
9/9/2015Joseph E. Turk, Jr.PresidentSell2,839$16.54$46,957.06View SEC Filing  
8/25/2015Joseph E Turk JrPresidentSell2,000$18.25$36,500.00View SEC Filing  
8/17/2015Robert S BrownInsiderSell10,825$18.30$198,097.50View SEC Filing  
8/14/2015Winifred L SwanSVPSell2,500$18.14$45,350.00View SEC Filing  
8/13/2015Jeffrey H BurbankCEOSell10,000$18.31$183,100.00View SEC Filing  
8/12/2015Jeffrey H BurbankCEOSell10,000$18.03$180,300.00View SEC Filing  
8/12/2015Joseph E Turk JrPresidentSell3,252$17.74$57,690.48View SEC Filing  
7/22/2015Joseph E Turk JrPresidentSell2,000$13.86$27,720.00View SEC Filing  
7/14/2015Winifred L SwanSVPSell2,500$14.71$36,775.00View SEC Filing  
6/23/2015Joseph E Turk JrPresidentSell2,000$15.36$30,720.00View SEC Filing  
6/18/2015Jeffrey H BurbankCEOSell20,000$15.56$311,200.00View SEC Filing  
6/15/2015Winifred L SwanSVPSell2,500$15.48$38,700.00View SEC Filing  
6/10/2015Joseph E Turk JrPresidentSell2,839$16.00$45,424.00View SEC Filing  
5/18/2015Winifred L SwanSVPSell2,500$16.65$41,625.00View SEC Filing  
5/12/2015Jeffrey H BurbankCEOSell10,000$16.44$164,400.00View SEC Filing  
4/21/2015Joseph E Turk JrPresidentSell1,950$18.40$35,880.00View SEC Filing  
4/17/2015Jeffrey H BurbankCEOSell10,000$18.08$180,800.00View SEC Filing  
4/16/2015Jeffrey H BurbankCEOSell10,000$18.31$183,100.00View SEC Filing  
4/8/2015Joseph E Turk JrPresidentSell1,500$18.34$27,510.00View SEC Filing  
3/26/2015Joseph E Turk JrPresidentSell1,150$16.94$19,481.00View SEC Filing  
3/18/2015Jeffrey H BurbankCEOSell20,000$17.40$348,000.00View SEC Filing  
3/10/2015Joseph E Turk JrPresidentSell1,500$16.44$24,660.00View SEC Filing  
2/25/2015Joseph E Turk JrPresidentSell2,082$17.88$37,226.16View SEC Filing  
1/27/2015Joseph E Turk JrPresidentSell2,350$18.70$43,945.00View SEC Filing  
1/14/2015Winifred L SwanSVPSell500$18.44$9,220.00View SEC Filing  
1/13/2015Joseph E Turk JrPresidentSell1,500$18.35$27,525.00View SEC Filing  
1/13/2015Winifred L SwanSVPSell666$18.35$12,221.10View SEC Filing  
12/29/2014Winifred L SwanSVPSell667$18.17$12,119.39View SEC Filing  
12/23/2014Joseph E Turk JrPresidentSell2,350$18.44$43,334.00View SEC Filing  
12/15/2014Joseph E Turk JrPresidentSell2,000$17.45$34,900.00View SEC Filing  
12/15/2014Kevin HershbergerCAOSell8,000$17.19$137,520.00View SEC Filing  
12/10/2014Joseph E Turk JrPresidentSell1,500$17.77$26,655.00View SEC Filing  
12/5/2014Jeffrey H BurbankCEOSell5,000$17.16$85,800.00View SEC Filing  
12/2/2014Robert S BrownInsiderSell34,700$17.44$605,168.00View SEC Filing  
12/1/2014Joseph E Turk JrPresidentSell24,762$17.04$421,944.48View SEC Filing  
12/1/2014Winifred L SwanSVPSell16,667$17.04$284,005.68View SEC Filing  
11/25/2014Joseph E Turk JrPresidentSell3,350$17.59$58,926.50View SEC Filing  
11/14/2014Joseph E Turk JrPresidentSell29,560$17.39$514,048.40View SEC Filing  
11/14/2014Winifred L SwanSVPSell17,167$17.37$298,190.79View SEC Filing  
11/12/2014Joseph E Turk JrPresidentSell26,261$16.27$427,266.47View SEC Filing  
11/12/2014Kevin HershbergerCAOSell11,056$16.58$183,308.48View SEC Filing  
11/7/2014Joseph E Turk JrPresidentSell24,761$16.25$402,366.25View SEC Filing  
11/3/2014Joseph E Turk JrPresidentSell5,717$15.50$88,613.50View SEC Filing  
10/23/2014Joseph E Turk JrPresidentSell3,550$14.55$51,652.50View SEC Filing  
10/23/2014Robert S BrownInsiderSell45,370$14.53$659,226.10View SEC Filing  
9/24/2014Joseph E Turk JrPresidentSell3,550$13.34$47,357.00View SEC Filing  
9/19/2014Jeffrey H BurbankCEOSell2,416$14.00$33,824.00View SEC Filing  
9/19/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
9/10/2014Kevin HershbergerCAOSell843$13.58$11,447.94View SEC Filing  
9/8/2014Jeffrey H BurbankCEOSell2,322$14.00$32,508.00View SEC Filing  
9/8/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
8/27/2014Joseph E Turk JrPresidentSell2,550$13.06$33,303.00View SEC Filing  
8/15/2014Winifred L SwanSVPSell2,500$13.60$34,000.00View SEC Filing  
8/7/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
8/7/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
7/24/2014Joseph E Turk JrPresidentSell3,550$13.50$47,925.00View SEC Filing  
7/18/2014Winifred L SwanSVPSell2,000$13.46$26,920.00View SEC Filing  
6/24/2014Joseph E Turk JrPresidentSell3,950$14.43$56,998.50View SEC Filing  
6/20/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
6/17/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
6/9/2014Winifred L SwanSVPSell9,228$14.00$129,192.00View SEC Filing  
6/5/2014Jeffrey H BurbankCEOSell5,000$14.00$70,000.00View SEC Filing  
6/5/2014Joseph E Turk JrPresidentSell1,500$14.00$21,000.00View SEC Filing  
6/5/2014Winifred L SwanSVPSell7,500$14.00$105,000.00View SEC Filing  
5/29/2014Joseph E Turk JrPresidentSell4,035$13.60$54,876.00View SEC Filing  
5/15/2014Winifred SwanSVPSell9,629$12.80$123,251.20View SEC Filing  
5/14/2014Winifred SwanSVPSell5,000$13.04$65,200.00View SEC Filing  
3/6/2014Robert FunariDirectorBuy10,150$14.72$149,408.00View SEC Filing  
10/21/2013Robert S BrownInsiderSell140,100$14.00$1,961,400.00View SEC Filing  
9/9/2013Thomas SheaSVPSell1,000$12.30$12,300.00View SEC Filing  
8/12/2013Thomas SheaSVPSell1,172$12.93$15,153.96View SEC Filing  
7/8/2013Thomas SheaSVPSell7,000$14.34$100,380.00View SEC Filing  
6/10/2013Thomas SheaSVPSell5,000$13.73$68,650.00View SEC Filing  
5/13/2013Thomas SheaSVPSell15,724$12.67$199,223.08View SEC Filing  
11/13/2012David S UtterbergDirectorSell184,204$11.58$2,133,082.32View SEC Filing  
11/2/2012David S UtterbergDirectorSell34,730$11.13$386,544.90View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for NxStage Medical (NASDAQ:NXTM)
Latest Headlines for NxStage Medical (NASDAQ:NXTM)
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) SVP Matthew W. Towse Sells 4,300 Shares
www.americanbankingnews.com - September 21 at 10:32 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Nxstage Medical, Inc. - NXTM
finance.yahoo.com - September 11 at 1:31 AM
americanbankingnews.com logoFY2017 EPS Estimates for NxStage Medical, Inc. Reduced by Analyst (NXTM)
www.americanbankingnews.com - September 8 at 6:50 AM
americanbankingnews.com logoResearch Analysts Issue Forecasts for NxStage Medical, Inc.'s Q2 2018 Earnings (NXTM)
www.americanbankingnews.com - September 7 at 11:36 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) President Sells $27,950.00 in Stock
www.americanbankingnews.com - September 5 at 8:52 PM
americanbankingnews.com logoNxStage Medical (NXTM) vs. Novadaq Technologies (NVDQ) Critical Analysis
www.americanbankingnews.com - September 3 at 12:04 PM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 30 at 6:42 PM
finance.yahoo.com logoNxStage Medical Announces FDA Clearance for Solo Home Hemodialysis Using NxStage® System One™
finance.yahoo.com - August 29 at 6:15 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Sees Large Drop in Short Interest
www.americanbankingnews.com - August 29 at 1:08 AM
finance.yahoo.com logoNxStage System One Now in Nine of Top Ten U.S. Nephrology Hospitals
finance.yahoo.com - August 25 at 9:32 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) SVP Sells $125,646.00 in Stock
www.americanbankingnews.com - August 23 at 8:04 PM
americanbankingnews.com logoContrasting NxStage Medical (NXTM) and Novadaq Technologies (NVDQ)
www.americanbankingnews.com - August 21 at 4:22 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of NxStage Medical, Inc. to Fresenius Medical Care for $30 Per Share is Fair to Shareholders
finance.yahoo.com - August 17 at 6:23 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Expected to Announce Quarterly Sales of $102.79 Million
www.americanbankingnews.com - August 16 at 6:48 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) SVP Winifred L. Swan Sells 3,500 Shares
www.americanbankingnews.com - August 15 at 8:00 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about NxStage Medical Inc.
finance.yahoo.com - August 15 at 4:38 PM
finance.yahoo.com logoNxStage Medical Partners Dialyze Direct for On-Site Dialysis
finance.yahoo.com - August 15 at 5:18 AM
finance.yahoo.com logoNXSTAGE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NxStage Medical, Inc.
finance.yahoo.com - August 15 at 5:18 AM
americanbankingnews.com logoBrokers Issue Forecasts for NxStage Medical, Inc.'s FY2017 Earnings (NASDAQ:NXTM)
www.americanbankingnews.com - August 14 at 5:08 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Downgraded by BTIG Research to "Neutral"
www.americanbankingnews.com - August 13 at 2:52 PM
finance.yahoo.com logoNxStage Kidney Care and Dialyze Direct to Provide On-Site Dialysis to Skilled Nursing Facility Patients in Ohio
finance.yahoo.com - August 12 at 6:31 AM
finance.yahoo.com logoNxStage Medical, Inc. – Value Analysis (NASDAQ:NXTM) : August 12, 2017
finance.yahoo.com - August 12 at 6:31 AM
finance.yahoo.com logoSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of NxStage Medical Acquisition - NXTM
finance.yahoo.com - August 12 at 6:30 AM
americanbankingnews.com logoQ4 2017 EPS Estimates for NxStage Medical, Inc. (NASDAQ:NXTM) Cut by Analyst
www.americanbankingnews.com - August 11 at 1:04 PM
finance.yahoo.com logoNXSTAGE MEDICAL, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - August 11 at 7:10 AM
americanbankingnews.com logoInsider Selling: NxStage Medical, Inc. (NASDAQ:NXTM) President Sells 1,000 Shares of Stock
www.americanbankingnews.com - August 10 at 8:38 PM
americanbankingnews.com logoResearch Analysts Set Expectations for NxStage Medical, Inc.'s FY2017 Earnings (NASDAQ:NXTM)
www.americanbankingnews.com - August 10 at 10:42 AM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Rating Lowered to Equal Weight at Stephens
www.americanbankingnews.com - August 9 at 7:40 AM
finance.yahoo.com logoCompany News For August 08, 2017 - Yahoo Finance
finance.yahoo.com - August 9 at 5:52 AM
prnewswire.com logoRowley Law PLLC is Investigating NxStage Medical, Inc. and its Board of Directors for Potential Breaches of ... - PR Newswire (press release)
www.prnewswire.com - August 9 at 5:52 AM
reuters.com logoFresenius Medical banks on home dialysis with $2 billion NxStage acquisition - Reuters
www.reuters.com - August 9 at 5:52 AM
prnewswire.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of NxStage Medical, Inc. (NXTM) - PR Newswire (press release)
www.prnewswire.com - August 9 at 5:52 AM
prnewswire.com logoWeissLaw LLP: NxStage Medical, Inc. Acquisition May Not Be in the Best Interests of NXTM Shareholders - PR Newswire (press release)
www.prnewswire.com - August 9 at 5:52 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of NxStage Medical, Inc. (NXTM)
finance.yahoo.com - August 9 at 5:52 AM
finance.yahoo.com logoNXSTAGE MEDICAL, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes the Acquisition by Fresenius Medical Care May be Unfair to Shareholders
finance.yahoo.com - August 9 at 5:52 AM
finance.yahoo.com logoWeissLaw LLP: NxStage Medical, Inc. Acquisition May Not Be in the Best Interests of NXTM Shareholders
finance.yahoo.com - August 9 at 5:52 AM
finance.yahoo.com logoRowley Law PLLC is Investigating NxStage Medical, Inc. and its Board of Directors for Potential Breaches of Fiduciary Duty
finance.yahoo.com - August 9 at 5:52 AM
americanbankingnews.com logoNxStage Medical, Inc. (NASDAQ:NXTM) President Sells $711,360.00 in Stock
www.americanbankingnews.com - August 8 at 7:44 PM
americanbankingnews.com logoNxStage Medical, Inc. (NXTM) Stock Rating Lowered by William Blair
www.americanbankingnews.com - August 8 at 7:00 AM
finance.yahoo.com logoHarwood Feffer LLP Announces Investigation of NxStage Medical, Inc.
finance.yahoo.com - August 8 at 2:37 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Concerning Whether the Sale of NxStage Medical, Inc. to Fresenius Medical Care for $30 Per Share is Fair to Shareholders
finance.yahoo.com - August 8 at 2:37 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of NxStage Medical, Inc. - NXTM
finance.yahoo.com - August 8 at 2:37 AM
finance.yahoo.com logoNxStage reports 2Q loss
finance.yahoo.com - August 8 at 2:37 AM
americanbankingnews.com logoNxStage Medical, Inc. (NASDAQ:NXTM) Receives Hold Rating from Northland Securities
www.americanbankingnews.com - August 7 at 8:02 PM
fool.com logoBuyout Bid Overshadows NxStage Medical's Losses
www.fool.com - August 7 at 6:29 PM
americanbankingnews.com logoCanaccord Genuity Lowers NxStage Medical, Inc. (NASDAQ:NXTM) to Hold
www.americanbankingnews.com - August 7 at 4:22 PM
fool.com logoWhy NxStage Medical, Inc. Is Skyrocketing Today
www.fool.com - August 7 at 12:50 PM
americanbankingnews.com logoCraig Hallum Downgrades NxStage Medical, Inc. (NXTM) to Hold
www.americanbankingnews.com - August 7 at 11:20 AM
americanbankingnews.com logoNxStage Medical (NXTM) versus Novadaq Technologies (NVDQ) Financial Survey
www.americanbankingnews.com - August 7 at 9:08 AM
americanbankingnews.com logoNxStage Medical, Inc. (NASDAQ:NXTM) Announces Quarterly Earnings Results
www.americanbankingnews.com - August 7 at 8:50 AM



NxStage Medical (NXTM) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff